image
Integra LifeSciences Holdings Corporation IART
Healthcare - Medical - Devices - NASDAQ - US
Watchlist
$ 21.87
0.83 %
$ 1.69 B
Market Cap
-243.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one IART stock under the worst case scenario is HIDDEN Compared to the current market price of 21.9 USD, Integra LifeSciences Holdings Corporation is HIDDEN

IART Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one IART stock under the base case scenario is HIDDEN Compared to the current market price of 21.9 USD, Integra LifeSciences Holdings Corporation is HIDDEN

IART Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one IART stock under the best case scenario is HIDDEN Compared to the current market price of 21.9 USD, Integra LifeSciences Holdings Corporation is HIDDEN

IART Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart IART

image
1M 0%
6M 20%
1Y -55.0%
3Y -192%
5Y -89%
All
$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 Mar
FINANCIALS
1.61 B REVENUE
4.47%
Growth Rates
1Year 4.47%
3Years 1.45%
5Years 1.20%
7Years 4.44%
10Years 5.66%
28.4 M OPERATING INCOME
-74.53%
Growth Rates
1Year -74.53%
3Years -47.58%
5Years -30.79%
7Years -6.30%
10Years -8.02%
-6.94 M NET INCOME
-10.25%
Growth Rates
1Year -10.25%
3Years -1.35%
5Years -2.63%
7Years -1.47%
10Years -1.88%
129 M OPERATING CASH FLOW
-7.55%
Growth Rates
1Year -7.55%
3Years -25.46%
5Years -19.11%
7Years 1.76%
10Years 5.00%
-391 M INVESTING CASH FLOW
-314.97%
Growth Rates
1Year -314.97%
3Years -34.27%
5Years -5.10%
7Years 15.02%
10Years -0.73%
238 M FINANCING CASH FLOW
203.45%
Growth Rates
1Year 203.45%
3Years 64.13%
5Years 29.84%
7Years -20.34%
10Years -0.20%
443 M REVENUE
16.23%
Growth Rates
1Year 4.47%
3Years 1.45%
5Years 1.20%
7Years 4.44%
10Years 5.66%
35.6 M OPERATING INCOME
537.14%
Growth Rates
1Year -74.53%
3Years -47.58%
5Years -30.79%
7Years -6.30%
10Years -8.02%
19.4 M NET INCOME
281.70%
Growth Rates
1Year -10.25%
3Years -1.35%
5Years -2.63%
7Years -1.47%
10Years -1.88%
50.7 M OPERATING CASH FLOW
125.66%
Growth Rates
1Year -7.55%
3Years -25.46%
5Years -19.11%
7Years 1.76%
10Years 5.00%
-4.25 M INVESTING CASH FLOW
59.13%
Growth Rates
1Year -314.97%
3Years -34.27%
5Years -5.10%
7Years 15.02%
10Years -0.73%
-7.15 M FINANCING CASH FLOW
64.10%
Growth Rates
1Year 203.45%
3Years 64.13%
5Years 29.84%
7Years -20.34%
10Years -0.20%
Balance Sheet Integra LifeSciences Holdings Corporation
image
Current Assets 1.08 B
Cash & Short-Term Investments 274 M
Receivables 272 M
Other Current Assets 536 M
Non-Current Assets 2.96 B
Long-Term Investments 0
PP&E 550 M
Other Non-Current Assets 2.41 B
6.78 %6.75 %13.27 %13.62 %59.59 %Total Assets$4.0b
Current Liabilities 922 M
Accounts Payable 82.5 M
Short-Term Debt 48.4 M
Other Current Liabilities 791 M
Non-Current Liabilities 1.57 B
Long-Term Debt 167 M
Other Non-Current Liabilities 1.4 B
3.31 %31.75 %6.70 %56.30 %Total Liabilities$2.5b
EFFICIENCY
Earnings Waterfall Integra LifeSciences Holdings Corporation
image
Revenue 1.61 B
Cost Of Revenue 728 M
Gross Profit 882 M
Operating Expenses 854 M
Operating Income 28.4 M
Other Expenses 35.4 M
Net Income -6.94 M
2b2b2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m00(200m)(200m)2b(728m)882m(854m)28m(35m)(7m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
54.77% GROSS MARGIN
54.77%
Averages
1Year 54.77%
3Years 58.23%
5Years 59.59%
7Years 60.28%
10Years 61.31%
1.76% OPERATING MARGIN
1.76%
Averages
1Year 1.76%
3Years 8.11%
5Years 9.63%
7Years 9.64%
10Years 9.19%
-0.43% NET MARGIN
-0.43%
Averages
1Year -0.43%
3Years 5.18%
5Years 7.26%
7Years 6.24%
10Years 5.63%
-0.45% ROE
-0.45%
Averages
1Year -0.45%
3Years 4.61%
5Years 6.54%
7Years 5.81%
10Years 5.58%
-0.17% ROA
-0.17%
Averages
1Year -0.17%
3Years 2.09%
5Years 2.89%
7Years 2.56%
10Years 2.39%
0.34% ROIC
0.34%
Averages
1Year 0.34%
3Years 2.85%
5Years 3.88%
7Years 4.06%
10Years 4.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Integra LifeSciences Holdings Corporation
image
300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -6.94 M
Depreciation & Amortization 141 M
Capital Expenditures -104 M
Stock-Based Compensation 24.4 M
Change in Working Capital 0
Others -8.21 M
Free Cash Flow 25 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Integra LifeSciences Holdings Corporation
image
Wall Street analysts predict an average 1-year price target for IART of $26.6 , with forecasts ranging from a low of $20 to a high of $40 .
IART Lowest Price Target Wall Street Target
20 USD -8.55%
IART Average Price Target Wall Street Target
26.6 USD 21.74%
IART Highest Price Target Wall Street Target
40 USD 82.90%
Price
Max Price Target
Min Price Target
Average Price Target
404035353030252520201515May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Integra LifeSciences Holdings Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
141 K USD 2
6-9 MONTHS
25.7 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.5 M USD 2
9-12 MONTHS
7. News
Notice to Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf PHILADELPHIA, March 22, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company. globenewswire.com - 1 week ago
Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. globenewswire.com - 3 weeks ago
Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade) Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs. seekingalpha.com - 4 weeks ago
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up IART delivers better-than-expected earnings in the fourth quarter of 2024. zacks.com - 1 month ago
INTEGRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART) on behalf of long-term stockholders following a class action complaint that was filed against Integra on September 12, 2023 with a Class Period from March 11, 2019 to May 22, 2023. Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the company. globenewswire.com - 1 month ago
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript seekingalpha.com - 1 month ago
Integra (IART) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates Integra LifeSciences (IART) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.89 per share a year ago. zacks.com - 1 month ago
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 1 month ago
Jan De Witte joins GHO Capital as Operating Partner Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. globenewswire.com - 1 month ago
Notice To Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf PHILADELPHIA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company. globenewswire.com - 1 month ago
Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025 PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. globenewswire.com - 1 month ago
8. Profile Summary

Integra LifeSciences Holdings Corporation IART

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.69 B
Dividend Yield 0.00%
Description Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Contact 1100 Campus Road, Princeton, NJ, 08540 https://www.integralife.com
IPO Date Aug. 16, 1995
Employees 4396
Officers Ms. Lea Daniels Knight Executive Vice President & Chief Financial Officer Laurene Isip Vice President of Global Corporate Communications & Public Relations Mr. Stephen Leonard Corporate Vice President of Global Operations & Supply Chain Mr. Jeffrey A. Mosebrook Senior Vice President of Finance & Principal Accounting Officer Ms. Mojdeh Poul President, Chief Executive Officer & Director Mr. Eric Ian Schwartz J.D. Executive Vice President, Chief Legal Officer & Secretary Dr. Stuart M. Essig Ph.D. Non- Executive Chairman Mr. Robert T. Davis Jr. Executive Vice President & President of Tissue Technologies Christopher Ward Senior Director of Investor Relations Mr. Michael J. McBreen Executive Vice President & President of Codman Specialty Surgical